Pop-Dot confirmed today that the agency has begun working with the world’s leader in drug delivery technology, Catalent, who serves 41 of the top 50 biotech companies in the world, and 48 of the top 50 pharmaceutical companies worldwide. Pop-Dot, a Wisconsin-based “brand strategy and innovation agency,” will reportedly provide Catalent with brand strategy, marketing, and advertising services.

“We’re thrilled to be working with such successful, fellow-innovators,” said Jason Fish, the President at Pop-Dot. “To put Catalent’s success into perspective, just consider that if you’ve taken any FDA-approved pharmaceutical product since 2004, there’s a 50% chance Catalent worked on it. That’s exceptional.”
Catalent’s locations in Europe, Asia, Latin America, and North America boast over 1,000 scientists who support 40% of recent new drug approvals. Across those 30+ global sites, the company makes or packages over 100 billion units annually.
“Although I can’t disclose the nature of our work with Catalent,” continued Pop-Dot’s President, “I can tell you that everyone at the agency is proud to be working alongside the dedicated and talented people of Catalent who have an entrepreneurial and forward-thinking culture that we greatly admire.”

(Article posted with permission of original author)